LBA39 Updated Efficacy and Safety Data from IMbrave050: Phase III Study of Adjuvant Atezolizumab (atezo) + Bevacizumab (bev) Vs Active Surveillance in Patients (pts) with Resected or Ablated High-Risk Hepatocellular Carcinoma (HCC)
Annals of Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined